Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 17, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-16

Reporting Person: Newton Charles W. (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$6.24	2031-02-04	Common Stock (3612000)		Direct
Option (right to buy)	$6.24	2031-02-04	Common Stock (190000)		Direct
Option (right to buy)	$6.24	2031-02-04	Common Stock (516000)		Direct

Footnotes

F1: 1/4 of the option shares shall vest on February 5, 2022, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.

F2: The shares subject to the Option will commence vesting upon the consummation of the Issuer's first underwritten public offering of its Common Stock under the Securities Act of 1933, as amended (the "Vesting Start Date"), and: (a) prior to the Vesting Start Date, none of the shares will be vested; (b) one forty-eighth (1/48th) of the shares subject to the option will vest on the one (1) month anniversary of the Vesting Start Date; and (c) thereafter, the option will become vested and exercisable with respect to an additional 1/48th of the shares thereafter on the same day of the month of the Vesting Start Date.